• linkedin
  • Increase Font
  • Sharebar

    Walgreens expands 90-day pharmacy program offering

    With the goal of driving better medication adherence and better outcomes by giving patients the choice of how to receive the medications, along with 24/7 pharmacist availability - Walgreens launched a new 90-day pharmacy program with EnvisionRx, the PBM division of EnvisionRxOptions.

    The alliance will give patients the ability to fill 90-day prescriptions at 8,200 Walgreens pharmacies.

    Jim Cohn, a spokesman for Walgreens told Drug Topics that the new program is another example of how the company is working closely with its partners to make the medications patients need more accessible and more affordable.

    According to Walgreens, the new program is a reflection of the company’s ongoing efforts to provide greater value, care and service to customers. and patients when, where and how they need it.  “We’re working closely with PBMs and health plans to provide greater benefits to both our pharmacy customers and their clients,” Cohn said.

    Walgreens has similar programs with Express Scripts (Smart90) and OptumRx (Optum Select 90.

    Matt Gibbs, EnvisionRx president of commercial and managed markets said Rx90 is a new program.

    Prior to its launch, the company conducted primary research to identify the key elements needed to make it successful, where other medication management programs have failed.

    “When you think about getting members to change their behaviors, a successful approach has to address all of the reasons that cause patients to be non-adherent to their care plans,” Gibbs said.

    Anthony Vecchione
    Anthony Vecchione is Executive Editor of Drug Topics.

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available